Bristol-Myers Squibb Co. and Bavarian Nordic formed an agreement providing Bristol-Myers Squibb an exclusive option to license and commercialize Prostvac, Bavarian Nordic’s investigational phase III prostate-specific antigen targeting immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer, in a deal worth up to $975 million.
Bristol-Myers Squibb and Bavarian Nordic form agreement for Prostvac
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
Two decades after uncovering the role of EGFR mutations in lung cancer, scientists are still grappling with lingering research questions.
Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.Â
Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.Â
